Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Formoterol for treatment of COVID-19
IRCT20170210032478N3Phase 3Completed
- Sponsor
- Masih Daneshvari Hospital
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of formoterol in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Masih Daneshvari Hospital. Primary endpoints: Five-day symptom improvement, Ten-day symptom improvement and 1 more. Started Apr 2020; status: completed.
02
Drugs
formoterol
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20170210032478N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20170210032478N3.